Emergex wins UK grant from Innovate UK to advance flu vaccine

Emergex Vaccines has been awarded a grant of £979,318 by Innovate UK to work on a new approach to developing vaccines for infectious diseases.
Designed to target components of the influenza virus that are common to all strains, the vaccine will also be suitable to target the outbreak of a new flu pandemic. The grant should cover 70 percent of the cost of developing the flu vaccine programme over a period of two years, and will be used to complete preclinical studies and manufacturing. Phase I clinical testing should commence in the first half of 2020.
“This Innovate UK grant provides endorsement of our flu vaccine programme and reinforces our belief that an innovative approach, using the very latest technologies, could help protect the public from this inevitable epidemic or pandemic health threat,” noted Professor Thomas Rademacher, co-founder, chief executive and chief scientific officer at Emergex.